



FY26 Full Year Results

August 2026

Pro Medicus (ASX:PME) | Leaders in Enterprise Imaging/Radiology Information Systems

pro♦medicus



GROUP HQ
Melbourne, AUS

EU HQ/R&D
Berlin, Germany

North American HQ
San Diego, CA USA

pro♦medicus



Table of Contents

• FY26 Highlights	4
• Financials	6
• Contract Wins	14
• Contract Renewals	21
• Implementations	23
• Investments & Partnerships	28
• AI Progress	31
• Products	36
• Clinical Outcomes	52
• Growth Strategy	54
• RSNA 2025	61
• Summary	65

FY26 Full Year Results | Year ended 30 June 2026 | A\$ unless otherwise stated | Page references are slide numbers

pro♦medicus



FY26 Highlights

pro♦medicus



FY26 Highlights

- **Financials** – Underlying Revenue +28%¹, Underlying EBIT +31%², Underlying NPAT +33%², Cash Conversion 91%, Cash & Other Financial Assets \$252m + 20%
- **Contract Wins** – 1 Europe, 9 US contracts signed worth total of \$407m
- **Renewals** – Renewed 6 out of 6 contracts on long term, 5-year extensions
- **Implementations** – On or ahead of schedule
- **Cardiology** – gaining traction UC Health Colorado, Vancouver Clinic & Others
- **New Products** – Digital pathology and AI optimized Reporting module
- **Investments** – 4DX and EIQ agreements
- **AI** – Breast cancer detection pending FDA clearance
- **Strong Pipeline** – Increased number of opportunities across all market segments

(1) Constant currency; (2) Underlying excludes FX and Fair value gains on investments

uchealth



Beth Israel Lahey Health



EchoiQ

pro⁺medicus



pro♦medicus



Financials

pro♦medicus



Results FY26 Financial Performance

Revenue
\$261.7M
up 22.9%

Underlying EBIT
\$196.1M
up 24.4%

Underlying EBIT Margin
74.9%
up 0.9pt

Underlying NPAT
\$144.7M
up 24.1%

Group earnings summary

A\$m	FY26	FY25	Change	%
Revenue	261.7	213.0	48.7	22.9%
Underlying EBIT	196.1	157.7	38.4	24.4%
Underlying EBIT margin	74.9%	74.0%	+0.9pt	-
Underlying NPAT	144.7	116.6	28.1	24.1%
Underlying NPAT margin	55.3%	54.7%	+0.6pt	-
Fair value gain financial assets & interest	174.2	0.1	174.1	
Net currency gains/(losses)	(1.9)	(2.0)	0.1	
Reported profit before tax	377.5	163.3	214.2	131.2%
Income tax expense	(112.2)	(48.1)	(64.1)	
Reported NPAT	265.3	115.2	150.1	130.3%

Revenue by region

A\$m	FY26	FY25	Change	%
Australia	19.0	17.7	1.3	7.3%
Europe	5.9	4.3	1.6	37.2%
North America	236.8	190.9	45.9	24.0%
Total revenue	261.7	213.0	48.7	22.9%

Underlying NPAT reconciliation

A\$m	Gross	Tax	Net
Fair value gain	174.2	(52.3)	121.9
Net currency gains/losses	(1.9)	0.6	(1.3)
Total adjustments	172.3	(51.7)	120.6
Reported NPAT			265.3
Underlying NPAT			144.7

Year ended 30 June 2026 | A\$ unless otherwise stated | Underlying excludes fair value movements on financial assets and net currency movements

Results FY26 Constant Currency

Revenue (constant currency)

\$273.5M

up 28.4% underlying

Underlying EBIT (constant currency)

\$206.0M

up 30.6% underlying

FX Impact on Revenue

\$(11.8)M

AUD/USD 0.6779 vs 0.6472

FX Impact on EBIT

\$(9.9)M

AUD/EUR 0.5812 vs 0.5950

Revenue by region (A\$m)	FY26 reported	FY26 constant currency	FX impact	FY25 reported	Underlying growth \$m	Underlying growth %
Australia	19.0	19.0	-	17.7	1.3	7.3%
Europe	5.9	5.8	0.1	4.3	1.5	34.9%
North America	236.8	248.7	(11.9)	190.9	57.8	30.3%
Total revenue	261.7	273.5	(11.8)	213.0	60.6	28.4%
Underlying EBIT (A\$m)	FY26 reported	FY26 constant currency	FX impact	FY25 reported	Underlying growth \$m	Underlying growth %
Underlying EBIT	196.1	206.0	(9.9)	157.7	48.3	30.6%
NPAT (A\$m)	FY26 reported	FY26 constant currency	FX impact	FY25 reported	Underlying growth \$m	Underlying growth %
Reported NPAT	265.3	275.2	(9.8)	115.2	160.0	138.8%
Underlying NPAT	144.7	154.5	(9.8)	116.6	37.9	32.5%

FY26 restated at FY25 average exchange rates | Underlying growth excludes the impact of currency movements and fair value gains/losses | A\$ unless otherwise stated

Results FY26 Balance Sheet and Shareholder Returns

Cash Reserves
\$216.1M
up 23.8%

Cash and Financial Assets
\$252.3M
up 19.7%

NTA per Share
\$4.10
up 81.4%

Total Dividend (franked)
69.0c
up 25.5%

Capital position

A\$m	FY26	FY25	Change	%
Cash reserves	216.1	174.5	41.6	23.8%
Cash and financial assets	252.3	210.7	41.6	19.7%
Borrowings	Nil	Nil	–	–
NTA per share (\$)	4.10	2.26	1.84	81.4%
Effective tax rate	29.7%	29.4%	+0.3pt	–


Dividends per share (franked)

Cents per share	FY26	FY25	Change	%
Interim dividend	32.0c	25.0c	+7.0c	28.0%
Final dividend	37.0c	30.0c	+7.0c	23.3%
Total dividend	69.0c	55.0c	+14.0c	25.5%

As of 30 June 2026 | A\$ unless otherwise stated | Dividends are fully franked | Growth calculated on FY25 comparatives

Results FY26 - Five-year Revenue Growth


Revenue by revenue stream




Revenue by type, FY22 to FY26 | A\$m |

Results FY26 Revenue Split and Forward Contracts

Revenue by geography




Forward contracts recurring revenue next five years



Revenue by geography, and forward contracts | A\$m | Forward contracts of A\$1.34bn over the next five years, up 41.3% in 12 months

Results FY26 Total Contract Value Signed



Total contract value by year

A\$m	New	Renewals	Total
FY22	100.0	57.0	157.0
FY23	88.5	15.5	104.0
FY24	245.0	19.0	264.0
FY25	511.0	169.0	680.0
FY26	407.0	141.0	548.0
Five years	1,351.5	401.5	1,753.0

FY26 in context

Second highest year on record, behind an exceptional FY25 (includes Trinity Health).

Five year TCV signed of \$1.75bn

Total contract value is minimum contracted revenue over the contract term - excludes exam volumes above contracted minimums.
FY26 comprises 10 new contracts and 6 renewals.
New contract wins and renewals signed in each financial year | A\$m at contracted minimums

Financial Performance – 5 Years

Revenue Reported	FY22	FY23	FY24	FY25	FY26	CAGR (%)
Australia	14.6	15.9	16.9	17.7	19.0	5%
Europe	5.2	4.4	4.1	4.4	5.9	3%
North America	73.7	104.6	140.6	190.9	236.8	26%
Total	93.5	124.9	161.5	213.0	261.7	23%

Revenue Constant Currency	FY22	FY23	FY24	FY25	FY26	CAGR (%)
Australia	14.6	15.9	16.9	17.7	19.0	5%
Europe	5.3	6.3	4.8	4.8	5.8	2%
North America	71.7	95.1	136.1	188.0	248.7	28%
Total	91.6	117.3	157.8	210.5	273.5	24%

Underlying	FY22	FY23	FY24	FY25	FY26	CAGR (%)
EBITDA	69.7	91.8	120.8	164.9	204.2	24%
% Margin	75%	73%	75%	77%	78%	1%
EBIT	62.4	83.9	112.3	157.7	196.1	26%
% Margin	67%	67%	70%	74%	75%	2%
NPAT	44.4	60.8	83.2	116.6	144.7	27%
EPS	42.5	58.2	79.7	111.6	138.5	27%
DPS	42.4	58.1	79.5	111.4	138.3	27%

Balance Sheet	FY22	FY23	FY24	FY25	FY26	CAGR (%)
Cash & cash equivalents	63.7	30.4	60.1	107.5	146.5	18%
Term Deposits	-	60.9	63.9	67.0	69.6	NM
Total	63.7	91.2	123.9	174.5	216.1	28%

pro♦medicus




Contract Wins

pro♦medicus



Contract Wins



New contracts: \$407m

 UCHealth Colorado \$170m / 10 years Full Stack + Cardiology	 Beth Israel Lahey Health \$90m / 7 years Full Stack	 RANT \$44m / 5 years Viewer	 BayCare \$25m / 7 years Archive	 University of Maryland \$23m / 5 years Viewer + Worklist	 Five contracts \$55m combined Heidelberg, Roswell Park, and Vancouver Clinic
---	---	---------------------------------------	---	--	--

Year ended 30 June 2026 | Total contract value at contracted minimums, A\$ | Excludes transaction volumes above minimums

Contract Win – UCHealth Colorado

- A\$170M 10-year deal, 2nd largest in company's history
- “Full Stack + 1” – Includes Visage 7 | Cardiology Imaging offering
- Highly respected hospital system based in Aurora Colorado
- University of Colorado Hospital – AMC Medical school and research center for Colorado University
- Went live in May 2026 – Hybrid AMC and IDN

uchealth

Contract Win – Heidelberg University

- A\$10M – 5-year deal
- Top German medical school and teaching hospital
- Affiliated German Cancer Research Institute largest cancer research centre in Europe
- Increased PME footprint in Germany/Europe
- Went live in April 2026



**UNIVERSITÄT
HEIDELBERG**
ZUKUNFT
SEIT 1386

Contract Win – Radiology Associates North Texas (RANT)

- A\$44M – 5-year deal
- Private, remote reading group based in North Texas
- One of the nation's largest and most innovative private practice radiology groups
- Breast Imaging live in April 2026
- Full go live – August 2026
- Greatly strengthens PME presence in private market



Contract Win – University of Maryland

- A\$23M – 5-year deal
- Academic Medical Center
- Based in Baltimore, Maryland
- Was a key reference site for Visage competitor
- 12 hospitals across Maryland, including the University of Maryland Medical Center and world-renowned R Adams Cowley Shock-Trauma Center



Contract Win – Beth Israel Lahey Health

- A\$90M – 7-year deal, 4th largest in company's history
- “Full Stack”
- Highly respected hospital system based in Boston, Massachusetts
- Academic medical centers and teaching, community and specialty hospitals
- Fourteen (14) hospitals and will include the world-renowned Dana-Farber Cancer Institute



pro♦medicus



Contract Renewals

pro♦medicus



Contract Renewals



Renewals and additions: \$144m

 \$37m / 5 years	 \$31m / 5 years	 \$28m / 5 years	 \$20m / 5 years	 ZWANGER-PESIRI RADIOLOGY \$16m / \$9m 5 years	 VISN 23 \$2.8m Worklist module added
--	--	--	--	---	---

All renewals for 5-year period at higher per transaction fee transaction

Year ended 30 June 2026 | Total contract value at contracted minimums, A\$ | Addition: \$2.8M VISN 23 Worklist module

pro♦medicus



Implementations

pro♦medicus



Implementations



Visage® 7 Go-Live Implementations: 16 go-lives



16 Go-Lives completed
4 Trinity Health cohorts,
BayCare



Live in 10 months
Signed July 2025,
Go-Live May 2026



FMOL, VISN 23
Two Cloud Migrations
Moved from On-Prem



European Go Live
Heidelberg University
Voted 12th best hospital
in the world



RSNA 2025
Busiest to date
Continued progress across
other –ologies, reporting and AI

Total contract value is minimum contracted revenue over the initial term and excludes transaction volumes above contracted minimums. FY26 comprises 16 go-lives, including four Trinity Health cohorts.

Year ended 30 June 2026 | Total contract value at contracted minimums, A\$ | Excludes transaction volumes above minimums

pro⁺medicus



Implementations – Progress at 30 June 2026

Announced	Customer	Contract Value (A\$)	Term	Implied Annualised (A\$)	Go- Live Target	Progress	% Implemented FY26
28-Nov-24	Trinity	\$330m	10 years	\$33m	4Q CY25	On Schedule	75%
04-Dec-24	Lurie's Children's Hospital	\$5m	7 years	\$1m	3Q CY25	On Schedule	100%
16-Jan-25	University of Kentucky	\$33m	9 years	\$4m	4Q CY25	On Schedule	100%
04-Feb-25	BayCare	\$53m	7 years	\$8m	1Q CY26	On Schedule	100%
03-Mar-25	Lucid Health	\$40m	7 years	\$6m	3Q/4Q CY25	On Schedule	100%
08-May-25	University of Iowa	\$20m	5 years	\$4m	4Q CY25	On Schedule	100%
03-Jul-25	University of Colorado	\$170m	10 years	\$17m	2Q CY26	On Schedule	100%
08-Oct-25	University Hospital Heidelberg	\$10m	5 years	\$2m	2Q CY26	On Schedule	100%
17-Nov-25	Radiology Associates North Texas	\$44m	5 years	\$9m	1Q CY26	On Schedule	10%
24-Nov-25	The Vancouver Clinic	\$13m	7 years	\$2m	3Q CY26	On Schedule	0%
08-Apr-26	University of Maryland	\$23m	5 years	\$5m	1Q CY27	On Schedule	0%
18-May-26	Beth Israel Lahey ⁽¹⁾	\$90m	7 years	\$13m	1Q CY27	On Schedule	0%
24-Nov-25	Roswell Park Cancer Centre	\$9m	7 years	\$1m	2Q CY26	On Schedule	100%
01-Jun-26	TidalHealth	\$16m	7 years	\$2m	4Q CY26	On Schedule	0%
12-Aug-26	St Luke's Health System	\$23m	7 years	\$3m	1Q CY27	On Schedule	0%

(1) Multiple cohorts

Implementations – Trinity Health Update

- Contract signed – November 2024
- Arguably, the largest CloudPACS in the world
 - National footprint, centralized in the cloud, high availability
 - Centralized workflow platform across the entire network, enables national reading across time zones
- Phased implementation – 7 cohorts; 5 cohorts complete (87%)
 - Cohort 1 – Oct 27 2025
 - Cohort 2 – Jan 19 2026
 - Cohort 3 – Apr 13 2026
 - Cohort 4 – June 1 2026
 - Cohort 5 – July 20 2026
- Cohorts 6 and 7 – remaining 13% completed by October 2026



Implementations – Competitive Advantage

- All implementations on or ahead of schedule
- Fast track methodology continues to deliver
- Large scale projects completed in under 1/4 to 1/5 the time of industry norm
- Delivers huge savings for client
- Free(s) PME staff for other jobs
- Reduces barrier to change
- Highly optimized hybrid model (onsite + remote)
- A key differentiator of Visage offering



pro♦medicus



Investments & Partnerships

pro♦medicus



Investment – 4DMedical (ASX:4DX)

- \$10m investment – hybrid debt and equity
- 2-year term maturing 31 July 2027
- Coupon rate of 12.5% PA
- \$20m payout if share price doubles
- Equity component if share price more than doubles ($> \$0.48$)
- Unrealised gain ~\$172m as of 30 June 2026



Investment – Echo iQ (ASX:EIQ)

- A\$10m initial investment in secured unlisted convertible notes at A\$1.05 per note
- Option to invest another A\$10m upon Echo IQ receiving FDA clearance of EchoSolv HF
- 2-year term maturing after issue date
- Coupon rate of 12.5% PA
- Options – 0.75 unlisted options per note with A\$1.35 exercise price

EchoiQ

pro♦medicus



AI Progress

pro♦medicus



AI in Healthcare

- Healthcare and AI – ideally matched
- Imaging at the vanguard of healthcare AI
- Highly regulated environment – FDA, CE, TGA
- Mission critical - zero downtime/zero errors
- AI must be imbedded in complex workflows to be used by clinicians
- AI must be trusted – can't be a black box




Visage 7 | AI

- PME/Visage ideally placed to benefit from AI
- Visage 7.0 desktop the “gate keeper” for image-based AI integration
- Visage used by ~ 11% of US market and growing
- Ability to imbed AI into core Visage 7 offering
- Capital light strategy sourcing best in breed algorithms



Visage 7 | AI

- Breast cancer detection algorithm co-developed with NYU – commercialisation pending FDA clearance
- Investment in Elucid for Cardiac CT AI
- Investments in 4DMedical and Echo IQ
- Research collaboration agreements with UCSF, Mayo, NYU and others
- Growing number of 3rd party AI integrations



AI – Research Leadership



Malte Westerhoff, PhD
Global Chief Technology Officer



Detlev Stalling, PhD
Head of Development



MingDe Lin, PhD
Clinical Research Manager,
North America

pro♦**medicus**




Products

pro♦**medicus**



Visage 7 One Platform – All Imaging

- Single viewer for ALL images in the medical record (EHR) – Enterprise Imaging
- Radiology/Cardiology/Pathology
- Non-radiology– reflected light – hi-res photos & videos
- Same code base as Visage 7 platform
- Increases Visage value proposition
- Growth opportunities within existing contracts



Radiology • Cardiology • Digital Pathology • Breast Imaging • Teleradiology • Specialty Workflow
Ophthalmology • POCUS • Dental • Remote Reading • Non-DICOM • Visible Light • Multimedia



pro+medicus






SPEED | FUNCTIONALITY | SCALABILITY

Competition – Legacy Technology


“Compress & Send”



Pro Medicus – Solution


“Streaming Technology”

Visage® 7 | CloudPACS



Driver – Massive Data Explosion

- Photon-Counting CT – .2 mm; 10,000+ images
- HD Breast Tomosynthesis – 6 GB+
- Digital Pathology – 10 GB+ with cystology up to 30 GB
- Optoacoustic Breast Ultrasound – 10 GB+
- Total Body PET Scan – 10 GB+
- 7T MRI – much larger than 3T



Driver – Radiologist Burnout – The New Epidemic

- Acute worldwide shortage of radiologists
- Reduced intake of radiology residents – fears AI would take over
- Larger datasets – more images to look at
- Work life balance post COVID – work from home mandatory part of the mix
- Many groups struggling to handle current workload, falling behind
- Groups starting to cut back on reporting contracts




Visage 7 CloudPACS

- Visage 7 – fully Cloud native
- Same ultrafast performance as on-premise
- Full Visage 7 functionality
- Security and scale of the cloud
- Suitable for all size implementations
- Pipeline opportunities mandating Cloud deployment
- Cloud vendor agnostic – large scale implementations in all three clouds – AWS, Azure and Google GCP
- Significant strategic advantage over competitors



Visage[®] 7

CloudPACS




pro+medicus

VISAGE IMAGING[®]


Visage 7 Open Archive

- Same highly scalable Visage 7 platform
- Interoperable – works in complex environments
- Enables choice of modular or single vendor solutions
- Visage 7 Open Archive integral part of “Full Stack” solution
- Pipeline – most opportunities include Visage 7 Open Archive
- Key component of Visage Cloud strategy
- Transaction based model with potential upside



Visage 7 Workflow

- Adds to Viewer and Open Archive modules
- Based on over 30 years experience in Workflow SW
- Allows PME to offer “full stack” solution
- Integral part of Visage CloudPACS SaaS solution
- Ability to interface with broad range of AI algorithms
- Sold in majority of new contracts
- Transaction based model with potential upside



Visage 7 | Reporting

- Announced at SIIM 2026
- First implementations during 2026
- Native, ultrafast, AI optimized reporting
- Intelligent AI tools improve quality and save valuable time
 - Draft From Prior
 - Revise tools
 - Auto Impression generation
 - Error checking



Visage[®] 7

Reporting



pro+medicus

 VISAGE IMAGING[®]


Visage 7 | Cardiology Imaging

- Cloud-based Workflow and Imaging Solution for Cardiology Imaging
- Same code base as Visage 7 platform
- Ultrafast, immediate access to massive Cardiology datasets
- Native Cardiology Imaging tools
- Advanced interoperability – export measurements to Epic Cupid



Visage® 7

Cardiology Imaging



pro+medicus

VISAGE IMAGING®

Visage 7 | Digital Pathology

- Native support within the Visage 7 Enterprise Imaging Platform
- Fully Cloud-based (Visage 7 | CloudPACS)
- Spatial computing support via Visage Ease VP for Apple Vision Pro
- Validation of IHE Digital Pathology Profile at the 2025 IHE-Europe Connectathon





VISAGE RIS

Visage RIS - Dr R Simpson (rsna) visage2 (2) © Visage General Hospital (ris.promed.com.au)

RECEPTION TECHNOLOGIST DOCTOR TRANSCRIPTIONIST SEARCH OFFICE CLAIMING SETUP

Recent Dr R Simpson

Appointments Requested Arrival Billing Banking

Region Northern Book Visage General Hospital Tue, 17-Oct-2017 AM PM Patient Procedure Cancelled Blocked Reset 1 2

Visage X-ray	Visage CT	Visage US Room 1	Visage US Room 2	Visage US Room 3	Visage Mammo
Tue, 17-Oct-2017 08:30 AM Blocked 09:00 AM 09:15 AM 09:30 AM Blocked 09:45 AM 10:00 AM 10:15 AM 10:30 AM 10:45 AM Blocked 11:00 AM 11:15 AM 11:30 AM 11:45 AM Blocked 12:00 PM 12:15 PM 12:30 PM 12:45 PM ADAMS, Mrs ROSE ... 01:00 PM 01:15 PM 01:30 PM 01:45 PM 02:00 PM 02:15 PM 02:30 PM 02:45 PM 03:00 PM 03:15 PM 03:30 PM 03:45 PM 04:00 PM 04:15 PM 04:30 PM 04:45 PM	Tue, 17-Oct-2017 08:30 AM 09:00 AM 09:30 AM 10:00 AM 10:30 AM SMITH, Mr John: C... 11:00 AM 11:30 AM 12:00 PM Lunch 12:30 PM Lunch 01:00 PM 01:30 PM 02:00 PM Non Contrast 02:30 PM 03:00 PM 03:30 PM 04:00 PM 04:30 PM	Tue, 17-Oct-2017 08:00 AM 08:15 AM 08:30 AM 08:45 AM 09:00 AM 09:15 AM 09:30 AM 09:45 AM 10:00 AM 10:15 AM 10:30 AM 10:45 AM 11:00 AM 11:15 AM 11:30 AM 11:45 AM 12:00 PM 12:15 PM 12:30 PM 12:45 PM 01:00 PM 01:15 PM 01:30 PM 01:45 PM 02:00 PM 02:15 PM 02:30 PM 02:45 PM 03:00 PM 03:15 PM 03:30 PM 03:45 PM 04:00 PM 04:15 PM 04:30 PM 04:45 PM	Tue, 17-Oct-2017 08:30 AM 09:00 AM 09:30 AM 10:00 AM 10:30 AM 11:00 AM 11:30 AM 12:00 PM 12:30 PM 01:00 PM	Tue, 17-Oct-2017 08:30 AM 09:00 AM 09:30 AM 09:45 AM 10:00 AM 10:15 AM 10:30 AM 10:45 AM 11:00 AM 11:15 AM	Tue, 17-Oct-2017 09:00 AM 09:15 AM 09:30 AM 09:45 AM 10:00 AM 10:15 AM 10:30 AM 10:45 AM 11:00 AM 11:15 AM

Edit Appointment

APPOINTMENT Mr John SMITH FOLIO 10.645 ACCESSION 10.1270

Tue, 17-Oct-2017 10:30 AM - 11:00 AM

Male 05-Oct-1977 (40y) H: (03) 1212-1211 Visage General Hospital Visage

450 Swan Street... Dr Doogie Ho (03) 9800-1231 Appointment(s) Medium

SUMMARY

Patient SMITH, Mr John 10.645 Referrer Dr Doogie Howser 0000000Y

Born: 05-Oct-1977 (40y) Practice

Male (03) 1212-1211 Address 23 Hollywood lane ThePlace RICHMOND VIC 3121 Australia

Address 450 Swan Street RICHMOND VIC 3121 Referral date 09-Oct-2017

View all details Referral period 12

Accession 10.1270

Order Status Arrived (1/1)

Save Cancel

Visage RIS

- Long term (5 year) contracts with Lumus (Primary Healthcare) and I-MED, the 2 biggest radiology providers in AUS
- Upside via client organic and M&A growth
- Increased market interest – new opportunities
- PME undisputed market leader



pro+medicus



pro⁺medicus



Clinical Outcomes

pro⁺medicus



Delivering Clinical Outcomes



Moving the Needle



Delivering Clinical Outcomes & Proven ROI



pro♦medicus



Growth Strategy

pro♦medicus




Growth Strategy




North American – TAM

- 690 Million exams performed per annum in the US
 - Growing by ~3% per year
 - In contrast, Visage customers are growing by ~8%
- Visage able to address 100% of TAM from a product perspective
- ~ 85% of TAM addressable from commercial perspective – “full stack”, cloud etc...
- Current market penetration is ~11% and growing
- Very large addressable runway



North American Pipeline



Pipeline Robust

In terms of quality and quantity of opportunities

Opportunities

Increased number of inbound RFPs

Network Effect

Further increased from recent high-profile wins in both Tier-1 academic and IDN markets

Prospects

Progressing through various stages of the cycle



Largest Footprint in AMC

2026/2027 Best Hospitals

(alphabetical order)

>50% of the Best Rated U.S. Hospitals
(11 out of 20) use Visage 7 for PACS



>50% of The Best Hospitals Use Visage

Out of the top rated U.S. hospitals (11 out of 20) use Visage 7 for PACS.

1	BRIGHAM AND WOMEN'S HOSPITAL	Brigham & Women's - Live Full PACS
2	MASSACHUSETTS GENERAL HOSPITAL	Mass General - Live Full PACS
3	MAYO CLINIC	Mayo Clinic - Live Full PACS <i>Rochester</i>
4	MAYO CLINIC	Mayo Clinic - Live Full PACS <i>Arizona</i>
5	MAYO CLINIC	Mayo Clinic - Live Full PACS <i>Florida</i>
6	Northwestern Medicine	Northwestern - Live Full PACS
7	NYU Langone Health	NYU - Live Full PACS
8	RUSH	Rush - Live BI PACS
9	UC San Diego Health	UCSD - Live Full PACS
10	UCLA Health	UCLA - Live Full PACS
11	UCSF Health	UCSF - Live Full PACS



pro+medicus



VISAGE IMAGING®


IDN Segment – Growing Footprint

- IDNs represent the largest segment of the market
- IDN clients across broad spectrum of opportunities from large, national, multi-state, to smaller regional
- Most recent IDN sales for more than one Visage product – many “full stack” +
- 100% cloud deployments since September 2020
- Increasing network effect in this important market segment



Private Market Segment

- Previously “dormant” due to increased M&A activity
- RANT (ARM) A\$44M 5-year deal
- Adds to A\$70M contracted in private market in FY25
- Confirms Visage platform suited to broad range of market segments
- Opens more opportunities in this market space



pro♦medicus




RSNA 2025

pro♦medicus



Visage Ease VP for Apple Vision Pro



"Underpins our belief that our technology is 18 to 24 months ahead of competitors, if not more."

Apple Store Event – RSNA 2025



Pro Medicus – RSNA 2025



pro♦medicus



Summary

pro♦medicus



Summary

- **Record Financials** – Underlying Revenue +28%¹, Underlying EBIT +31%², Underlying NPAT +33%². Cash Conversion 91%, Cash & Other Financial Assets \$252m + 20%
- **Cloud** – Huge strategic advantage over competitors
- **Contract Wins** – Majority “full stack”, 10 contracts signed worth total of A\$407m
- **Renewals** – Renewed 6 out of 6 contracts on long term, 5-year extensions
- **Implementations** – All on schedule, we have proven implementation & support capability
- **Cardiology** – Gaining traction with Full stack +1 for UColorado, Vancouver Clinic, MedStar Health
- **New Products** – Visage 7 Reporting, Digital Pathology, increasing use cases for Visage Ease VP for Apple Vision Pro
- **Investments** – Broadens and deepens product offering with 4DX and EIQ agreements
- **AI** – Breast cancer detection pending FDA clearance, ideally positioned to leverage AI
- **Strong Pipeline** – Increased number of North American opportunities across all segments

(1) Constant currency; (2) Underlying excludes FX and Fair value gains on investments

uchealth



Beth Israel Lahey Health



EchoiQ

pro+medicus



promedicus



Thank You